IFITM3 and small cell lung carcinoma: These findings establish that IFITM3 upregulates MHC-I expression by promoting NLRC5 expression and facilitating its nuclear trafficking, thereby enhancing antigen presentation and improving immunotherapy efficacy in SCLC.